Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cougar Biotechnology

Latest From Cougar Biotechnology

Fortress Biotech: A Drug Financing Experiment Expands

Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.

Business Strategies Financing

J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A

Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.

BioPharmaceutical Clinical Trials

Puma triples on neratinib adjuvant breast cancer data

Puma Biotechnology's stock tripled in after-hours trading on 22 July after the company said it would seek regulatory approval based on Phase III results for its tyrosine kinase inhibitor neratinib in a Phase III clinical trial for the extended adjuvant treatment of breast cancer.


BioNotebook: Puma CEO sees sale as option, Tesaro drops, Can-Fite gains on study results

'Tis the season to dump good and bad news just before the holidays. Despite the upbeat headline in the company's press release, Tesaro reported mixed results for a late-stage experimental drug. Can-Fite BioPharma had better news. And Puma Biotechnology's CEO, a man with a love of big cat names, vows to do what's right for his shareholders.

Gastrointestinal Dermatology
See All

Company Information